Novo Nordisk

• Should These Drug Companies Pay a Dividend?

  By Chris Hodge - May 22, 2013 | Tickers: AGN, RDY, NVO

  Dividends are the nectar of the gods, delivered to shareholders as a symbol that wealth is attainable by everyone. However, even a hardcore dividend addict such as I will admit that there are times a company should hold off on paying a dividend. The following is an examination of a few companies in the drug manufacturing sector and my conclusion about their dividend arrangement.

  Use the Money to Grow

  Allergan more »

• A New Drug Sales Model

  By Reuben Brewer - May 20, 2013 | Tickers: NVO, PFE, TEVA |

  Pfizer (NYSE: PFE) is trying a new sales paradigm, selling direct to patients. If this effort works, it could completely change the pharmaceutical industry.

  Little blue pills

  One of Pfizer's best selling drugs is Viagra, which is used to treat erectile dysfunction. That particular ailment carries material social stigma and the pills, which are still under patent protection for many more years, can be expensive. That has proven to more »

• Good News For Health Care Stocks

  By Reuben Brewer - May 17, 2013 | Tickers: CAH, CVS, NVO

  New research shows that Medicaid coverage leads to an increased use of health care services. That's not surprising, but it does have big implications for health care stocks.

  The Oregon Study

  The New England Journal of Medicine recently released the results of an important study. The Oregon Study, as it's called, tracked that state's test of randomly assigning lower-income adults into two groups, one that received Medicaid more »

• Does the Healthcare Industry mean Stability?

  By tarun bachhawat - May 14, 2013 | Tickers: BDX, COV, NVO

  A leading medical technology company, Becton, Dickinson and Company's (NYSE: BDX) earnings were better than expected. It is one of the few medical companies that is able to deliver organic growth in a challenged healthcare industry. 

  A decent quarter

   

  Becton Dickinson reported revenue of $2 billion for the quarter and profit of $275.6 million, beating Wall Street's estimate by $0.04 per share. Revenue from sales in more »

• Will Obesity Drugs Gain Soon?

  By Brandy Betz - May 14, 2013 | Tickers: ARNA, NVO, OREX, VVUS

  Things are beginning to look slightly up for obesity drugmaker Vivus (NASDAQ: VVUS) -- mere weeks before a competing drug from Arena (NASDAQ: ARNA) hits the market.

  Vivus shares soared nearly 10% last Wednesday despite lackluster first quarter results. That’s because CEO Leland Wilson expressed an interest in finding a big pharma partner for the faltering Qsymia, which had a meager sales of $4.1 million in the quarter and more »

• Why This Stock's Crash is a Buying Opportunity

  By Lee Samaha - May 13, 2013 | Tickers: AGN, NVO, REGN, VRX

  It’s been a varied reporting season with a general uptrend in markets accompanying more than a few profit warnings. If you’ve been holding some of these names before the disappointments then it has been painful. The good news is that these situations can create buying opportunities. I think Allergan (NYSE: AGN) is a case in point, and here is why.

  Allergan’s Outlook

  It was almost a tale more »

• The Ups and Downs of Diabetes

  By Tyler Wofford - May 8, 2013 | Tickers: ABT, MRK, NVO

  Recently, I have focused in on some companies that play a major role in diabetic's lives like mine. The financial implications of this disease are astounding, and have presented what seems to be a great opportunity for investors. Today, I will discuss the earnings results of some of the largest players involved with the disease. 

  Let's get the biggest surprise (to me) out of the way. I have more »

• One Soda a Day Keeps Your Health Away

  By Tyler Wofford - May 2, 2013 | Tickers: KO, NVO, PEP

  Medscape is reporting the results of studies showing how just one soda each day can increase a person's chance of developing type 2 diabetes by as much as 25%. While this isn't necessarily surprising, the American Heart Association recommends not drinking more than 450 calories a week of sugar-sweetened beverages.

  That's three 12-ounce cans of PepsiCo (NYSE: PEP). Let's look at these soda companies and maybe more »

• Investing in the Prepaid Debit Card Revolution

  By Charles Tamburello - May 1, 2013 | Tickers: AXP, GDOT, JNJ, NTSP, NVO, PFE, TSS, WMT

  As a nation, we are currently in the midst of remarkable changes in the utilization of payment instruments. Electronic payment in the form of prepaid debit and stored value cards is currently the fastest growing niche in the financial sector. In fact, the number of prepaid card payments increased by 22 percent per year from 2006 through 2009. According to the Mercator Advisory Group, the amount of money placed on more »

• Trounce the Market With This Diabetes Care Company

  By Greg Williamson - April 28, 2013 | Tickers: BDX, LLY, NVO, SNY

  Diabetes currently affects an estimated 350 million people worldwide. This number is projected to grow to well over 500 million people by 2030.

  Diabetes is a very serious disease that results from high levels of glucose caused by the body not being able to effectively produce insulin (type 1 diabetes) or use insulin (type 2 diabetes). Diabetes is a leading cause of a wide variety of complications including kidney failure more »

• "The Most Sustainable Company in the World"

  By Tyler Wofford - April 25, 2013 | Tickers: BMY, LLY, MDT, NVO

  In January of 2012, Business Magazine released a list of the most sustainable companies in the world. You might be surprised to see who topped their list. I was surprised that it wasn't a company like Apple, but rather a company in the pharmaceutical industry. As a type 1 diabetic, I understand the costs that go along with the disease. However, even I was surprised to see a company more »

• How to Profit From Increasing Obesity

  By Lee Samaha - March 19, 2013 | Tickers: COV, MCD, NVO, PEP, SNY

  Note: A previous version of this article incorrectly stated the effect of Novo Nordisk's type 2 diabetes treatment. The mistake has been corrected below.

  Funnily enough, I think that long term investors should be investing in the long term. In this article I’m going to discuss obesity, its prevalence and suggest some of the stocks that might be bought and avoided as a consequence.

  Obesity Prevalence

  Everyone loves more »

• Top # 10: International Companies (ADRs)

  By Rohit Gupta - March 18, 2013 | Tickers: BUD, AZN, GSK, NVS, NVO, SNY

  A list of Top 10 International companies, with ADRs (American Deposittory Receipts) listed in the US. While all large international brands – a synopsis of their unique competitive advantage and long term moat

  1. Anheuser-Busch (NYSE: BUD) : juggernaut in the global beer market with leadership position in four of the top five beer profit pools (United States, Canada, Brazil, and Mexico). Further, strength of ABI's focus brands (Budweiser, Stella Artois more »

• How This Drugmaker Will Deal With A Diabetes Delay

  By Reuben Brewer - March 1, 2013 | Tickers: JNJ, NVO, SNY

  Novo Nordisk (NYSE: NVO) recently got some bad news from the Food and Drug Administration (FDA). The FDA requested additional information about a key insulin product that some expect to delay its launch until at least 2015. That's a big delay, but one the company can probably handle.

• Still a Buy, Despite the Tresiba Setback

  By Nauman Aly - February 25, 2013 | Tickers: AZN, BMY, NVO, SNY

  Shares of Novo Nordisk (NYSE: NVO) are trying to recover from a recent sell-off that occurred after the FDA rejected its new drug Tresiba -- citing lack of a pre-approval cardiovascular outcomes study. Tresiba is an insulin analog, which is injected subcutaneously three-times a week to help control the blood sugar level of those with diabetes. Shares plummeted almost 15% on this disappointing news. But the real question now is if more »

• What’s Moving These Biotech Stocks?

  By Brian Nichols - February 12, 2013 | Tickers: NVO, PPHM, REGN, SNY

  Typically, it doesn't take a lot for a stock to trade with gains/losses of more than 5% in a session; it can be caused by an analyst's remarks, sometimes it's caused by earnings, or maybe it’s just a technical response. Sometimes the moves are warranted and other times they are not. Therefore, I am looking at several moves to determine if the stocks are presenting more »

• No Sign of a Slowdown at This Recession Resistant Company

  By Lee Samaha - February 7, 2013 | Tickers: AGN, JNJ, NVO, COO, VRX

  I must confess I am finding the current market to be one of the most frustrating periods of my investing life. I’ve always liked a defensive growth stock, but nowadays they seem to be so expensive that the only thing left to do is refrain from buying and sulk in the corner for a while. However, I can’t complain too much about Allergan (NYSE: AGN), as it’s more »

• The Expense Of Diabetes: Is It Worth It?

  By Tyler Wofford - February 7, 2013 | Tickers: ABT, LLY, JNJ, MDT, NVO

  With studies showing 33% of Americans with diabetes or pre-diabetes, it is obvious that the industry should be booming. Like most fields there is stiff competition in the industry. I recently wrote a piece explaining why it appears these companies should be good investments. Since then earnings have been released, so let’s see how they stack up now.

  Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO)  are the more »

• Alas, Hamlet! A Diabetes Drugmaker to Renew the Faith

  By BA McKenna - February 5, 2013 | Tickers: BMY, NVO

  “Something is rotten in the state of Denmark,” is a line from Shakespeare’s Hamlet. If the character who uttered those words were an investor, his faith in Denmark would be renewed by the long-term stock performance -- and future potential -- of Novo Nordisk (NYSE: NVO).  

  Novo Nordisk, which has a $103.8 billion market cap, is the world's biggest maker of diabetes drugs. In 2012, 78% of the Danish more »

• Stocks for MLK Day

  By Erick Santos, M.D., Ph.D. - January 18, 2013 | Tickers: COST, GILD, GOOG, NVO, WFM

  Monday is Rev. Martin Luther King, Jr. Day, a day in which we should think of racial unity and follow Reverend Martin Luther King, Jr.’s vision for a better future. Even though MLK was not known as a stock investor, I would imagine he would have had some preference for companies that are good corporate citizens and the promise of some of the biotech companies that may help improve more »

• Page 1 of 3
• »